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Abstract: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous 
system, traditionally considered to be an autoimmune, demyelinating disease. Based on this 
understanding, the initial therapeutic strategies were directed at immune modulation and 
inflammation control. At present, there are five licensed first-line disease-modifying drugs and 
two second-line treatments in MS. Currently available MS therapies have shown significant 
efficacy throughout many trials, but they produce different side-effect profiles in patients. Since 
they are well known and safe, they require regular and frequent parenteral administration and 
are associated with limited long-term treatment adherence. Thus, there is an important need 
for the development of new therapeutic strategies. Several oral compounds are in late-stage 
development for treating MS. Fingolimod (FTY720; Novartis, Basel, Switzerland) is an oral 
sphingosine-1-phosphase receptor modulator which has demonstrated superior efficacy compared 
with placebo and interferon β-1a in Phase III studies and has been approved in the treatment 
of MS. We summarily review the oral compounds in study, focusing on the recent development, 
approval and the clinical experience with FTY720.
Keywords: multiple sclerosis, oral compounds, fingolimod, fty720, sphingosine 1, phosphate, 
patient satisfaction
Introduction
Multiple sclerosis (MS) is a chronic, inflammatory, immune-mediated disease of the 
central nervous system (CNS). Disease onset usually occurs in young adults, and it is 
more common in females (3:1). The incidence of the disease varies worldwide, with 
a prevalence that ranges between 2 and 150 per 100,000 depending on the country 
or specific population, affecting up to 2.5 million people worldwide.1 Although the 
incidence varies, MS is the most nontraumatic common cause of neurological disability 
and impairment in young patients in Western Europe and North America.2
Most patients (80%) present with a relapsing and remitting course (RRMS), 
which is characterized by recurring attacks of acute focal neurological deficits or 
exacerbations of existing deficits (relapses) followed gradually by partial or full 
recovery (remission).3 The multifocal nature of the disease manifests clinically as 
a range of sensorimotor, cerebellar, visual, sphincteric, brain stem, cognitive, and 
neuropsychiatric symptoms. After 10–20 years, approximately half of these patients 
convert to the secondary progressive (SPMS) phase of the disease, in which there is 
acceleration of disability accumulating irreversible neurologic deficits in the absence 
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of clinical relapses.4 The remaining 20% with progressive 
clinical deterioration from the onset of the disease have 
primary progressive MS (PPMS).
Even though the immunopathogenesis of  MS is complex 
and still unclear, it has been supposed that RRMS is char-
acterized by strong inflammation activity and PPMS and 
SPMS are thought to be dominated by axonal degeneration 
in the absence of overt inflammation which is most likely a 
result of oxidative damage and/or increased susceptibility 
to injury caused by the process of myelin sheath loosening.5 
Many different immune cells are involved in the pathogenesis 
of MS, including T cells, B cells, and macrophages.6 Given 
the prominence of inflammatory changes in acute MS lesions, 
therapy of the disease has focused particularly, for the past 
three decades, on anti-inflammatory strategies. Thus, seven 
compounds have once-daily licenses for treating MS and they 
especially target the inflammatory component of the disease. 
Thus all compounds licensed for treating MS have as prin-
ciple target the inflammatory component of the disease.
Treatment of RRMS typically consists of direct symptom 
management, brief corticosteroid administration for acute 
exacerbations, and the regular use of disease-modifying 
drugs (DMDs). Currently approved immunomodulator 
treatments for RRMS include glatiramer acetate (GA) and 
recombinant interferons (IFNβ) (IFNβ-1a Avonex®, IFNβ-1a 
Rebif®, IFNβ-1b Betaseron®, Extavia®) that represent the 
gold standard in modifying the course of MS. Natalizumab 
Mitoxantrone and fingolimod  are also available for treatment 
of MS as second-line therapy in more severe disease. Since 
MS is a currently incurable, chronic disease, long-term DMD 
therapy requires commitment from patients to continue their 
treatment indefinitely. At present, all currently approved MS 
treatments are injected (subcutaneously or intramuscularly) 
or are given by intravenous infusion that can be associated 
with reduced convenience and compliance, and with injec-
tion- or infusion-related adverse effects (AEs). Nevertheless, 
in clinical practice, DMDs treatments are frequently associ-
ated with suboptimal response in terms of efficacy. The exist-
ing medications are only partially effective at preventing MS 
relapses and in particular, at slowing disability progression. 
Patients treated with interferons often experience several side 
effects and these DMDs for MS require long-term, regular 
injection or monthly parenteral infusions, which may be 
uncomfortable and inconvenient for the patient.7
Given the limitations of current interventions, manage-
ment of MS could be significantly improved by new treat-
ments that influence not only the immune system but also the 
pathologic changes in the CNS while also being amenable 
to oral administration, possibly avoiding the drawbacks of 
parenteral administration. Thus there is an important need 
for new therapeutic strategies, not only those that may offer 
greater patient satisfaction such as oral medications and 
monoclonal antibodies, but also agents intended to promote 
neuroprotection and neurorepair. Fingolimod (FTY720) could 
be one such potential treatment, combining these both aspects. 
The objective of the present paper is to review compounds 
that have successfully completed Phase III clinical trials and 
to focus on FTY720, which has recently been approved.
Oral MS therapies in development
A number of potential therapies for MS are now in late-stage 
development. New and novel therapeutic agents are being 
trialed in MS centers worldwide. These include not only oral 
agents for relapsing and progressive forms of the disease, 
but also monoclonal antibodies. To improve adherence to 
DMD and especially to improve the therapeutic compliance 
and quality of life of patients, the development of oral agents 
would be welcome if they are at least as effective as the cur-
rently available injectable therapies. Several oral therapies 
are currently under evaluation in clinical trials. The most 
promising agents are listed in Table 1.
Within these compounds, two agents have already been 
submitted for regulatory approval (fingolimod, cladribine), 
with different outcomes. Regulatory applications for fin-
golimod were submitted in December 2009 and the drug 
received approval from the FDA on September 21, 2010.8 
On January 20, 2011, the Committee for Medicinal Products 
for Human Use (CHMP) adopted a positive opinion, recom-
mending that a marketing authorization for fingolimod be 
granted, intended for the treatment of adult patients with 
RRMS with high disease activity. At present, fingolimod is 
available in Russia and the US.
Applications for cladribine as an oral therapy for MS were 
submitted to the European Medicines Agency and the US 
FDA in 2009. However, in December 2009, the FDA issued 
a “refuse to file” letter to the manufacturers of cladribine 
(Merck KGaA) indicating that additional information was 
required before a further application could be submitted. 
In July 2010, the FDA accepted the resubmitted cladribine 
application and granted the drug priority review status. In 
the same month, the Russian Federal Service on Surveil-
lance in Healthcare and Social Development approved 
cladribine for use in RRMS with a similar approval being 
granted by the Australian Therapeutic Goods Administra-
tion in  September 2010.9 Yet cladribine received a negative 
 European  recommendation by the CHMP on September 23, 
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2010. Following this feedback from regulatory authorities, it 
has become challenging for the company to continue pursuing 
the global approval process of cladribine tablets.
Cladribine
Cladribine, a synthetic deoxyadenosine analog, is an oral 
immunomodulatory agent that produces targeted, sustained 
reduction of T and B lymphocytes. Cladribine is already 
approved for the treatment of leukemias and lymphomas.
Short-course therapy with cladribine tablets was inves-
tigated for RRMS in the CLARITY study (CLAdRIbine 
Tablets treating multiple sclerosis orallY). CLARITY was 
a Phase III, randomized, double-blind, placebo-controlled, 
multicenter, 96-week study with three parallel groups to 
assess the efficacy of cladribine tablets in patients with 
RRMS according to the diagnostic McDonald criteria. The 
cladribine tablets dosing regimen consisted of two or four 
short courses per year (cumulative dose of 3.5 and 5.35 mg/
kg over the 96-week study, respectively). Treatment with 3.5 
and 5.25 mg/kg cladribine tablets significantly reduced the 
annualized relapse rate (relative reduction: 57.6% and 54.5% 
vs placebo, respectively, both P , 0.001) and resulted in 
significantly more relapse-free patients (79.7% and 78.9% 
vs 60.9%, respectively; odds ratio [OR]: 2.53 and 2.43, both 
P , 0.001).10 Three outcomes of activity were detected on 
magnetic resonance imaging (MRI): T1 gadolinium-enhancing 
lesions, active T2 lesions, and combined unique lesions 
(all P , 0.001 vs placebo). Lymphopenia occurred more 
frequently in patients treated with cladribine tablets at both 
dosages than with placebo.11 Despite the lymphopenia, the 
overall incidence of infections was similar across treatment 
groups. There were no cases of herpes zoster in the placebo 
group compared with eight and 12 cases of herpes zoster in 
the 3.5 mg/kg and 5.35 mg/kg groups, respectively. However, 
all cases were dermatomal and self-limiting. Neoplasms 
occurred in ten cases, all of them in cladribine-treated patients 
at both doses, compared with no patients in the placebo group. 
One patient treated with cladribine tablets had reactivation of 
latent tuberculosis and died. The use of cladribine may have 
contributed to this reactivation, and tuberculosis screening 
measures were immediately introduced subsequently.
Fumaric acid
Fumaric acid (FA), BG12, is an unsaturated dicarboxylic 
acid, isomeric to maleic acid, which acts as an intermediate in 
the Krebs cycle. Its exact mechanism of action is still unclear, 
but it appears to induce depletion of peripheral blood leuko-
cytes owing mainly to a reduction in number of T cells.
In vitro studies indicate that fumaric acid esters (FAEs) 
induce a shift from T helper (Th)1 to Th2 cytokines as part 
of their treatment effect.12 In an open-label, prospective study 
involving ten patients with RRMS, FA produced significant 
reductions from baseline in the number (P , 0.05) and 
volume (P , 0.01) of Gd-enhancing lesions after 18 weeks 
of treatment with a target dose of 720 mg/day; this effect 
persisted throughout the second 48-week treatment phase at 
half the target dose, following a 4-week washout period.13
In a 24-week, double-blind, randomized, placebo-
 controlled Phase IIb study in RRMS patients (n = 257), MRI 
analysis revealed a significant and dose-dependent reduction 
of brain lesion activity, particularly after treatment with 
the 720-mg dosage. In comparison to placebo, this group 
Table 1 Summary of oral therapies in late stage development (Phase III) for the treatment of multiple sclerosis
Compound Dose regimen Molecule and mechanism Potential adverse effects
Cladribine Once daily for  
2–4 weeks per year
Adenosine deaminase-resistant purine nucleoside analog;  
preferentially reduces lymphocyte subpopulations; produces  
sustained reduction of lymphocyte T and B subtypes
Myelosuppression and 
infection
BG-12 Three times a day,  
every day
Unsaturated dicarboxylic acid, isomeric to maleic acid;  
appears to induce depletion of peripheral blood leukocytes  
owing mainly to a reduction of T cells; neuroprotective effects
Hepatotoxicity
Teriflunomide Once daily, every day Active metabolite of leflunomide; blocks de novo pyrimidine  
synthesis by inhibiting dihydroorotate dehydrogenase in  
T cell and other rapidly dividing cell populations, leading  
to a decrease in DNA synthesis
Pancytopenia, 
hepatotoxicity
Laquinimod  
(ABR-215062)
Once daily, every day Modulates the balance of the T-helper (Th) cells 1 and 2;  
induction of transforming growth factor β; inhibits infiltration  
of Cd4+ T cells and macrophages into CNS
Hepatotoxicity, 
proinflammation
Fingolimod  
(FTY720)
Once daily, every day Structural analog of sphingosine 1-phosphate receptor  
agonist myriocin; interferes with cell traffic between  
organs and blood, preventing migration to target sites
Lymphopenia, infection, 
bradycardia, increased airway 
resistance, macular edema, 
hepatotoxicity
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demonstrated ∼70% reduction in Gd-enhancing lesions and 
a 50% reduction in new or enlarging T2 lesions and new 
T1 hypointense lesions.14 The most commonly observed AEs 
were flushing, nasopharyngitis, headache, nausea, diarrhea, 
fatigue, pruritus, upper abdominal pain, and hot flush, with 
evidence of a dose-related influence on the frequency of 
most of these AEs.
A multicenter, 2-year randomized, double-blind, placebo-
controlled, dose-comparison, Phase III study was started in 
Europe and in North America to determine the long-term 
safety and efficacy of BG-12. This included the DEFINE 
(Efficacy and Safety of Oral BG00012 in Relapsing– 
Remitting Multiple Sclerosis) and the CONFIRM (Efficacy 
and Safety Study of Oral BG00012 With Active Reference 
in Relapsing–Remitting Multiple Sclerosis) trials, which also 
contained a GA group to compare BG-12 with an established 
therapy. The DEFINE study has been completed and results 
will soon be reported.
Teriflunomide
Teriflunomide is the active metabolite of leflunomide. 
Leflunomide blocks de novo pyrimidine synthesis by 
inhibiting dihydroorotate dehydrogenase in T cell and other 
rapidly dividing cell populations, leading to a decrease in 
DNA synthesis.15 Leflunomide is licensed for the treatment 
of rheumatoid arthritis and is also effective in experimental 
autoimmune neuritis and rat experimental autoimmune 
encephalomyelitis (EAE).16,17
A 36-week, randomized, double-blind,  placebo-controlled, 
parallel-group trial assessed the safety and efficacy of this 
new drug on MS patients. One hundred and seventy-nine 
patients (157 with RRMS, 29 with SPMS) were treated with 
the following: placebo (n = 61), teriflunomide 7 mg/day 
(n = 61), teriflunomide 14 mg/day (n = 57) for 36 weeks. 
Treatment with teriflunomide 7 or 14 mg/day resulted in 
significant suppression of .61% of MRI activity relative to 
placebo (P , 0.03 at 7 mg/day and P , 0.001 at 14 mg/day). 
The annualized relapse rate between placebo and terifluno-
mide 14 mg/day was similar to that reported for IFN-β and 
GA (32%). The higher dose of teriflunomide (14 mg/day) 
appears to be more effective than the 7 mg/day dose, in 
terms of relapse rate, although no dose effect was observed 
on primary endpoints such as Gd-enhancing lesions and 
new/enlarging T2 lesions.18 A large randomized, double-
blind, placebo-controlled Phase III parallel group study has 
recently been completed (TEMSO). Patients with RRMS 
or PRMS (n = 1088) were randomized (1:1:1) to receive 
 placebo, teriflunomide 7 mg/day or 14 mg/day for 108 weeks. 
The annualized relapse rates were 0.539, 0.370, and 0.369 in 
the placebo, 7 mg, and 14 mg groups, respectively. Thus, the 
relative risk reductions in the 7 mg and 14 mg groups versus 
placebo were 31.2% (P = 0.0002) and 31.5% (P = 0.0005), 
respectively. Sustained disease progression was reached in 
27.3% of the placebo patients, in 21.7% of the 7 mg patients, 
and in 20.2% of the 14 mg patients. The relative risk for 
sustained progression was significantly reduced by 29.8% 
versus placebo only in the 14-mg group (P = 0.0279).19 AEs 
reported more frequently in the treatment groups than in the 
placebo group were: neutropenia, nasopharyngitis, alopecia, 
nausea, increase in alanine aminotransferase, paresthesia, 
back and limb pain, diarrhea, and arthralgia.
Trials investigating teriflunomide in clinically isolated 
syndrome are underway as combination studies of terifluno-
mide with IFN-β or GA. This combination study seems 
to be really meaningful, as it explores the possibility of 
using teriflunomide as add-on therapy.
Laquinimod
Laquinimod is a novel synthetic compound with oral bioavail-
ability, that is in development as an oral formulation for the 
treatment of MS. Laquinimod was effective in a rat model 
of EAE, in which its efficacy was ascribed to modulation of 
the balance of Th1 and Th2 cells inducting the transforming 
growth factor β.20 However, the exact mechanism of action 
in MS patients is still unclear. The efficacy of laquinimod 
was studied in two Phase II studies. The first Phase II trial 
showed inconclusive results on the effect of the 0.3 mg dose 
and led to further exploration of the therapeutic dose in an 
additional Phase IIb study. The second study was a Phase IIb, 
multinational, randomized, double-blind, parallel-group, 
placebo-controlled 36-week study, evaluating the efficacy, 
tolerability, and safety of two daily oral doses (0.3 and 
0.6 mg) of laquinimod (as compared to placebo) in subjects 
with RRMS. Three hundred and six patients were random-
ized, 98 subjects to laquinimod 0.3 mg, 106 to laquinimod 
0.6 mg, and 102 to placebo. The statistical analysis on the 
intention-to-treat (ITT) population for the primary endpoint 
demonstrated a statistically significant treatment effect of 
laquinimod 0.6 mg compared to placebo (P = 0.0048), with a 
reduction of 40% in the cumulative number of Gd-enhancing 
lesions at weeks 24, 28, 32, and 36. A nonsignificant treat-
ment effect of 8% was observed with laquinimod 0.3 mg 
(P = 0.6740). A statistically significant reduction of treat-
ment effect of laquinimod 0.6 compared to placebo was 
demonstrated for other MRI-related endpoints, defined in 
the protocol as secondary endpoints.21 Given these results, 
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the sponsor has moved forward with Phase III clinical trials 
of laquinimod at the 0.6 mg/day dose.
Based on a thorough review of all laquinimod clinical data 
available to date, the primary safety concerns include poten-
tial hepatotoxicity and a possible pro-inflammatory effect. 
Four serious AEs (SAEs) were reported: pleuritis, Budd–
Chiari syndrome, pituitary adenoma with hemorrhage, and 
a possible diagnosis of Crohn’s disease.  Pharyngolaryngeal 
pain, dyspepsia, and ankle edema were also observed. 
Laboratory abnormalities seen in Phase II laquinimod stud-
ies include elevated white blood count, elevated fibrinogen 
levels, and a trend towards decreased hemoglobin, elevated 
liver enzymes, and increased amylase. The first of the 
two Phase III studies of laquinimod is called ALLEGRO, 
a multinational, multicenter, randomized, double-blind, 
placebo-controlled study evaluating the safety and efficacy 
of laquinimod 0.6 mg/day in RRMS.
Analysis of the primary endpoint in the completers 
and evaluable cohorts showed a reduction in annualized 
relapse rate (ARR) of 23% (P , 0.0024). Statistically 
significant differences have been detected in terms of sus-
tained progressions and brain atrophy, with a 32.8% reduc-
tion of brain loss in the treatment group (P , 0.0001)22. 
The second Phase III study (BRAVO), is a multinational, 
multicenter, randomized, parallel-group study in RRMS to 
assess the efficacy, safety, and tolerability of laquinimod 
0.6 mg/day compared with placebo in a double-blind design 
and with IFN-b-1a (Avonex) in a rater-blinded design. 
The present study showed sustained 3-month confirmed 
progression of disability,  a 33.5% reduction for laquini-
mod versus placebo (P = 0.04), and a 28.7% reduction 
(P = 0.09) with IFN versus placebo. An additional adhoc 
analysis to examine how robust this finding was, showed 
a similar effect on 6-month confirmed progression of 
disability, with a 40.6% reduction with laquinimod (P 
= 0.04) versus placebo and a 28.3% reduction with IFN 
versus placebo (P = 0.14). There was a 22% reduction with 
laquinimod versus placebo (P = 0.062) in Gd+ T1 lesions 
of Gd enhancing lesions and a 19% reduction in new T2 
lesions (P = 0.037). As would be expected based on prior 
experience, the IFN had an even larger effect on these 
parameters, with a 60% reduction in Gd+ lesions and a 
52% reduction in T2 lesions.23
All the Phase III trials regarding the drugs described 
above have been recently completed and are waiting for regu-
latory approval. In the next section, we focus on fingolimod 
which has been recently approved both in the US and Europe 
and could change the therapeutic treatment of MS.
Introduction to the compound
Fingolimod (FTY720) is an oral drug with a novel mechanism 
of action and unique immunological and neurobiological 
properties. Fingolimod is a structural analog of sphingosine 
that does not impair T and B cell activation, proliferation, 
and effective function, but interferes with cell traffic between 
lymphoid organs and blood.24 Moreover fingolimod is a lipo-
philic compound that can cross the blood–brain barrier, and 
research suggests that its neuroprotective properties might 
be a reflection of its ability to directly interact with specific 
receptors on neurons and glia.25 Following preclinical studies 
in animal models of organ transplantation, fingolimod was 
first evaluated for the prevention of allograft rejection in 
renal transplant patients, but Phase III trials failed to show 
benefit over standard treatments.26 The encouraging results 
obtained from animal models of experimental autoimmune 
encephalomyelitis (EAE) provided the rationale for clinical 
evaluation in humans, and one Phase II proof-of-concept 
study confirmed the favorable effect of fingolimod oral 
therapy on standardized measures of disease activity in 
patients with RRMS.
Chemistry and pharmacodynamics
Fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-
 propanediol) is an immunosuppressive natural product derived 
from myriocin, a metabolite isolated from the fungus Isaria 
sinclairii, used as a drug in Oriental medicine.27 This com-
pound is a sphingosine-1-phosphate (S1P) receptor  modulator. 
S1P is produced by the phosphorylation of sphingosine by 
ubiquitously expressed sphingosine kinases, a breakdown 
product of the cell membrane constituent sphingomyelin. It 
is present at concentrations of 100 to 1000 nmol/L in blood 
and, as with most small lipids, is preferentially bound to 
albumin and other plasma proteins.28 S1P could act both as 
second messenger and as an extracellular ligand for a family 
of plasma membrane G protein-coupled receptors (GPCR).29 
There are five known S1P receptor subtypes, S1P
1–5
, and 
these are expressed on a wide range of cell types, including 
lymphocytes and neural cells (Table 2). Each S1P receptor 
subtype is associate with at least one subclass of G protein, 
which activate different intracellular signaling pathways.30 
The receptors S1P
1–3
 are widely expressed by a variety of 
tissues, whereas S1P
4
 is exclusively found on lymphoid and 
hematopoietic tissues and S1P
5
 is mainly expressed in the 
CNS.31 The ubiquitous expression of S1P receptors and their 
coupling to different G proteins explains the varied biological 
effects of the S1P/S1P-receptor system.32 In particular, S1P1 
expressed on lymphocytes regulates the normal departure of 
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lymphocytes from lymphoid tissues,33 whereas S1P recep-
tors expressed in the CNS have been shown to modulate 
several functions, such as neurogenesis, neural function, 
and migration.31 This may explain the possible clinical AEs 
that agents targeting the S1P receptor system, including 
fingolimod, can potentially induce. As a structural analog of 
natural sphingosine, fingolimod after ingestion can undergo 
rapid phosphorylation in vivo, especially in the liver, by 
sphingosine kinase-2 to produce the phosphorylated form of 
the compounds. The latest can bind four of the five receptor 
subtypes with high affinity: S1P
1
, S1P
3
, S1P
4
, and S1P
5
.34 
After the interaction with the agonist, the S1P1 receptor is 
internalized and can no longer bind to its natural circulating 
ligand, S1P, inducing a long-lasting internalization, ubiq-
uitination, and intracellular degradation of the receptors, 
rendering the cells unresponsive to endogenous S1P.35 The 
effects of fingolimod reflect the ubiquitous expression of 
S1P receptors and is shown on different levels, primarily 
the immune system and CNS. Following administration, 
blood concentration increases slowly to reach peak values at 
8–36 hours post-dosing. The elimination half-life of fingoli-
mod averages 8.8 days, so a once-daily dosing is permitted. 
Clearance of fingolimod depends mainly on hepatic oxidative 
metabolism and none of the identified metabolites possess 
immunomodulatory activity.35 The main pharmacodynamic 
effect of fingolimod consistently observed in human studies 
has been temporary reversible lymphopenia.36,37
Clinical efficacy
On the basis of the demonstrated potency of fingolimod in 
human organ transplantation,37 preclinical studies in various 
EAE models were designed.38 These studies demonstrated 
the capability of fingolimod in preventing and treating EAE. 
Delivery of fingolimod from the day of immunization or at a 
presymptomatic disease stage prevents the development of 
neurological signs in both monophasic and relapsing forms of 
EAE.38,39 Fingolimod is currently being assessed in one of the 
largest Phase III MS study programs ever undertaken, having 
shown promise in a Phase II, 6-month placebo-controlled 
study in patients with relapsing MS in which oral fingolimod, 
when compared with placebo, significantly reduced ARR and 
inflammatory activity according to MRI scans (Table 3).
Phase II studies
The first study evaluating the activity of fingolimod in 
patients with RRMS was a randomized, double-blind, 
placebo-controlled, 6-month study.40 The study was designed 
to explore safety and tolerability, and the treatment effect 
on MRI lesion parameters but not clinical outcomes. In 
the core study, patients were randomly assigned, in a 1:1:1 
Table 2 Distribution and functions of S1P receptors26
Receptors Cellular distribution Fingolimod binding Key functions
S1P1 (EDG1) • Lymphocytes, mast cells, eosinophils; 
• Neurons, astrocytes oligodendrocytes microglia; 
•  Atrial myocytes, endothelium smooth muscle cells, 
Schwann cells
Yes •  Lymphocyte egress from secondary 
lymphoid organs
• Neural cell migration/function 
•  Embryonic development of 
cardiovascular and nervous systems
• Blood vessel formation
• Endothelial barrier function
S1P2 (EDG5) •  Neurons, microglia, astrocytes
• Smooth muscle cells, Schwann cells
No • vascular tone
• Endothelial barrier function 
•  Inner ear maintenance affecting hearing 
and balance
• Nerve conduction
S1P3 (EDG3) • Neurons, astrocytes microglia
• Atrial myocytes, endothelium, smooth muscle cells
• Lung
• Kidney
• Intestine
• Cartilage
• Schwann cells
Yes • Endothelial barrier function
• Neural cell migration/function
S1P4 (EDG6) • Leukocytes
• Schwann cells
Yes Unknown
S1P5 (EDG8) • Oligodendrocytes, microglia
• Astrocytes
Yes • Oligodendrocyte function 
• Natural killer cell migration
Abbreviations: EDG, endothelial differentiation sphingolipid G-protein-coupled receptor; NK, natural killer; S1P, sphingosine-1-phospate.
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ratio, to 1.25 mg of fingolimod, 5.0 mg of fingolimod, or 
a matching placebo once daily given as oral capsules. The 
intention-to-treat (ITT) population comprised 277 patients of 
which 255 (92%) completed the study. The primary endpoint 
of the study was the total number of Gd-enhanced lesions per 
patient recorded on T1-weighted MRI at monthly intervals 
for 6 months. Secondary MRI variables included the total 
volume of Gd-enhanced lesions per patient, the proportion 
of patients with Gd-enhanced lesions, the total number of 
new lesions per patient on T2-weighted images, changes in 
lesion volume on T2-weighted images, and brain volume 
from baseline to month 6. Clinical endpoints included the 
number of patients remaining free of relapse, the ARR, and 
the time to the first relapse.
The total cumulative numbers of lesions per patient on 
post-baseline, monthly Gd-enhanced, T1-weighted MRI 
scans were lower in both fingolimod groups than in the pla-
cebo group (P , 0.001 for the 1.25-mg dose and P = 0.006 
for the 5.0-mg dose). At month 6, the proportion of patients 
who were free of Gd-enhanced lesions was greater in both 
fingolimod groups than in the placebo group (P , 0.001 
for both comparisons). Regarding the clinical endpoint, 
significant improvements over placebo were observed in 
the fingolimod groups, including a relative reduction in 
the ARR (by 53% in the 5.0-mg group and by 55% in the 
1.25-mg group).
After the core study completion, patients could enter a 
dose open-label, uncontrolled, active-drug study  extension. 
Placebo recipients were re-randomized to one of the FTY720 
doses; those already receiving FTY720 continued at the 
same dose.41,42 During the study visits over months 15–24, 
patients receiving FTY720 5.0 mg were switched to 1.25 mg 
because a benefit-risk assessment indicated that the higher 
dose offered no efficacy advantage and possibly a less favor-
able safety profile.
Of the 250 patients who entered the extension, 189 
(75.6%) completed to month 24 and 173 (69%) to month 
36. In the group of patients who switched from the placebo 
group to the fingolimod group, the number of Gd-enhanced 
lesions decreased markedly following initiation of fingoli-
mod treatment to 0.4 at month 12 and remained low (0.1) at 
month 36. The relapse rate decreased to a level comparable 
with that of patients treated with fingolimod in the core study. 
The proportion of patients free from Gd-enhanced lesions in 
the placebo/fingolimod group was 50% at baseline, 47% at 
month 6, and 89% at month 36. The proportions of patients 
free from Gd-enhanced lesions in the fingolimod 1.25 mg and 
5.0/1.25 mg groups at baseline were 52% and 48%, respec-
tively; at month 36, the corresponding proportions were 
88% and 89%, respectively. In the continuous fingolimod 
groups, the mean number of Gd-enhanced lesions was 3.2 at 
baseline, 1.4 at month 6, and 0.2 at month 36 in the 1.25 mg 
group, and 2.6 at baseline, 0.4 at month 6, and 0.3 at month 
36 in the 5.0/1.25 mg group. The mean number of new T2 
lesions acquired across all treatment groups was 0.6 at month 
24 (since month 12) and 0.7 at month 36 (since month 24). 
 Considering clinical outcomes at month 36, the ARR was 0.20 
and 0.21 in the fingolimod 1.25 mg and 5.0/1.25 mg groups, 
Table 3 Summary of fingolimod trials
Study Study design Treatment in study Primary endpoints Eligibility criteria Main results
Kappos et al40 Phase II, 6-month,  
double-blind,  
parallel-group,  
placebo-controlled,  
multicenter
Fingolimod 5 mg po, qd 
Fingolimod 
1.25 mg po, qd 
Placebo
Total no of Gd+  
lesions on T1w  
MRI at month 6
RRMS, SPMS 
18–60 years 
EDSS 0–6, no  
evidence of relapse  
in the last 30 days
Patients free from 
Gd+ lesions: 82%*
Cohen et al, 
(TRANSFORMS)43
Phase III, 12-month,  
double-blind,  
double-dummy,  
parallel-group,  
active-controlled,  
multicenter
Fingolimod 
1.25 mg po, qd 
Fingolimod 
0.5 mg po, qd 
IFNBeta-1a 30 μg 
im, qw
ARR over 
12 months
RRMS 
18–55 years 
EDSS 0–5.5, recent  
history of relapse
ARR: 0.20*; 0.16* 
Patients free from 
relapses: 79.8%*; 82.6*
Kappos et al, 
(FREEDOMS)44
Phase III, 24-month,  
double-blind,  
parallel-group,  
placebo-controlled,  
multicenter
Fingolimod 
1.25 mg po, qd 
Fingolimod 
0.5 mg po, qd 
Placebo
ARR over 
24 months
RRMS 
18–55 years 
EDSS 0–5.5, recent  
history of clinical  
relapse
ARR: 0.16*; 0.18* 
Patients free from 
relapses: 74.7 ± 2.2%* 
70.4 ± 2.3*
Note: *P , 0.001. 
Abbreviations: ARR, annualized relapse rate for confirmed relapses; EDSS, Expanded Disability Status Scale; Gd+, Gadolinium-enhanced; IFNBeta-1a, interferon-b-1a; 
im, intramuscular; MRI, magnetic resonance imaging; po, orally; qd, every day; qw, once a week; RRMS, relapsing–remitting multiple sclerosis; SPMS, secondary progressive 
multiple sclerosis; T1w, T1-weighted.
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respectively, and 0.31 in the placebo/fingolimod group. The 
proportion of patients relapse-free at month 36 was 68% in 
the fingolimod 1.25 mg group and 73% in the fingolimod 
5.0/1.25 mg group rather than an estimated 51% of patients 
in the placebo/fingolimod group at month 36.
Phase III studies
On the basis of the results obtained from the Phase II studies, 
two multicenter, randomized, double-blind Phase III trials 
were designed.43,44 As the results suggest that the therapeutic 
benefits attributed to fingolimod might exceed those expected 
from approved disease-modifying injectable therapies such as 
IFN-β or GA, the Trial Assessing Injectable Interferon versus 
FTY720 Oral in Relapsing–Remitting Multiple  Sclerosis 
(TRANSFORMS)43 was designed to directly test this 
 hypothesis. In this 12-month, double-blind, double-dummy 
study, they randomly assigned 1292 RRMS patients between 
18 and 55 years of age according to the McDonald Criteria, 
who had a recent history of at least one relapse in the last 
year before screening, to receive either oral fingolimod at a 
daily dose of either 1.25 or 0.5 mg or intramuscular interferon 
beta-1a at a weekly dose of 30 μg. The primary efficacy 
endpoint was the ARR. Key secondary endpoints were the 
number of new or enlarged lesions on T2-weighted MRI scans 
at 12 months and the time to confirmed disability progression 
taken as a progression of disability that was sustained for at 
least 3 months. In all, 1153 patients (89%) completed the 
study, and 1123 (87%) continued to receive the assigned study 
drug. There was a significantly greater reduction in the ARR 
in both fingolimod groups than in the interferon group. The 
ARR was lower with fingolimod (0.5 mg: 0.16; 1.25 mg: 0.20) 
than with IFN-b-1a (0.33; P , 0.001). More patients treated 
with fingolimod remained free from relapses (80%–83%) 
compared with IFNb-1a (69%; P , 0.001). The propor-
tion of patients with confirmed disability progression was 
low and similar in all groups (6%–8%). Over the treatment 
period of 12 months, patients in both fingolimod groups had 
fewer new or enlarged hyperintense lesions on T2-weighted 
images than those receiving IFNb-1a (mean number, 0.5 mg 
group 1.7; 1.25 mg group 1.5; IFN-B group 2.6; P , 0.001 
and P = 0.004, respectively). The number of patients free 
from Gd+ lesions was also lower in those taking fingolimod 
(0.5 mg: 90.1%; 1.25 mg: 91.2%) compared with those 
taking IFNb-1a (80.8%; P , 0.001 for both groups).43
The second Phase III study investigating fingolimod 
was the FTY720 Research Evaluating Effects of Daily Oral 
Therapy in Multiple Sclerosis (FREEDOMS),44 a 24-month, 
double-blind, placebo-controlled randomized study. 
One thousand, two hundred and seventy-two patients were 
enrolled, who had RRMS defined as the McDonald Criteria, 
between 18 to 55 years of age, having a score of 0 to 5.5 
on the Expanded Disability Status Scale and had had one 
or more relapses in the previous year or two or more in the 
previous 2 years. Patients received oral fingolimod at a dose 
of 0.5 mg or 1.25 mg daily or placebo. As in the TRANS-
FORMS study, the primary endpoint was the ARR, and the 
secondary endpoint was represented by the time to disability 
progression. MRI measures of inflammation, burden of dis-
ease, and tissue destruction in patients were also analyzed. 
One thousand and thirty-three patients (81.2%) completed 
the 24-month study. All clinical and MRI-related efficacy 
endpoints significantly favored both doses of fingolimod over 
placebo, and there were no significant differences in efficacy 
between the two fingolimod doses: the aggregate ARR was 
lower with fingolimod at a dose of 0.5 mg (0.18) and fingoli-
mod at a dose of 1.25 mg (0.16) than with placebo (0.40), 
representing relative reductions of 54% and 60%, respec-
tively, in the aggregate ARR (P , 0.001 for both groups). In 
the fingolimod groups as compared with the placebo group, 
the time to first relapse was longer, the risk of relapse was 
reduced, and proportionately more patients remained free 
of relapse during the 24-month period. Fingolimod reduced 
the risk of disability progression, confirmed after 3 months, 
over the 24-month study period (hazard ratios: 0.68 for the 
1.25-mg dose and 0.70 for the 0.5-mg dose, P , 0.02).44 The 
cumulative probability of disability progression (confirmed 
after 3 months) was 17.7% for 0.5 mg of fingolimod, 16.6% 
for 1.25 mg of fingolimod, and 24.1% for placebo. At month 
24, patients receiving fingolimod had fewer new or enlarged 
hyperintense lesions on T2-weighted images than those in 
the placebo group (mean number: 0.5; for 1.25 mg: 2.5; for 
placebo: 9.8; P , 0.001). Fingolimod was also superior to 
placebo with regard to other MRI measures of disease activity 
as Gd+ enhancing lesions.43 Interestingly, in patients treated 
with fingolimod, the reduction in brain volume was less than 
in patients treated with placebo.
Safety and tolerability
The safety profile of fingolimod has been extensively studied, 
and the available data indicate that the drug has a relatively 
good safety profile. It is clear that the incidence of AEs for 
fingolimod is dose-dependent.40–43,44 In the Phase III trials, 
the incidence of AEs was approximately the same across 
all study groups. AEs related to fingolimod included infec-
tions, particularly respiratory, urinary tract, and herpes virus 
infections, increased levels of alanine aminotransferase, 
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 bradycardia and atrioventricular block at the time of treatment 
initiation, hypertension, and macular edema. The incidence 
of serious AEs was comparable among the study groups, 
with the exception of the TRANSFORMS trial,42 in which 
serious AEs were more frequent in patients assigned to the 
higher dose of fingolimod (1.25 mg; 11%) than in those 
receiving 0.5 mg (7%).
However, the pathophysiology of macular edema in 
patients treated with fingolimod is still unclear; macular 
edema was confirmed in 13 patients receiving fingolimod in 
Phase III trials, of which 11 were treated with 1.25 mg. Most 
cases occurred within the first 3–4 months and resolved after 
treatment discontinuation.43,44
As expected, the drug decreased peripheral blood lym-
phocyte counts to 20%–30% of baseline values. Lymphocyte 
counts remained stable throughout the treatment period, and 
returned to baseline values within weeks after treatment dis-
continuation. As a consequence of the effects of fingolimod 
on circulating lymphocyte, the drug apparently increased the 
risk of infections. In Phase III trials, the overall incidence 
of infections was similar across the study groups, between 
51%–72%. Mild and moderate upper and lower respiratory 
tract infections occurred more frequently among patients 
receiving fingolimod. In the FREEDOMS study, herpes virus 
infections were reported in similar proportions across study 
groups (1.25 mg: 5.8%; 0.5 mg: 8.7%; placebo: 7.9%). On 
the contrary, in the TRANSFORMS study, these were more 
common in the 1.25-mg group (5.5% of patients) than in the 
0.5-mg and IFN-b-1a groups (2.1% and 2.8%, respectively). 
Most herpes virus infections were mild, but a total of six 
serious AEs were reported, including one case of fatal dis-
seminated varicella zoster virus infection and one case of 
fatal herpes simplex virus type 1 encephalitis both in patients 
assigned to fingolimod 1.25 mg. Both patients were undergo-
ing concomitant corticosteroid treatment when the infection 
occurred.43,44 Thus, a possible increase in the risk of reactiva-
tion of latent herpes should be investigated when considering 
fingolimod treatment. Besides lymphopenia, asymptomatic 
elevation of liver enzyme levels was the most frequent 
laboratory abnormality and occurred in a dose- dependent 
manner within the whole range of doses investigated. In 
clinical studies, alanine aminotransferase levels returned to 
normal values after treatment discontinuation. In all these 
cases, other signs or symptoms of significant hepatocellular 
injury were not observed.43,44 Moreover, fingolimod induced a 
small, dose-dependent increase in the airway resistance upon 
treatment initiation, with no evidence of further progression 
with continuous dosing.40–44
As was expected according to previous findings, rarely 
symptomatic, dose-dependent reduction in heart rate was 
observed within 6 hours after administration of the first 
dose. This drop in heart rate was already evident after 
1 hour post dosing, reached a maximum mean reduction of 
approximately 10 bpm at 4–5 hours, and began to attenuate 
at 6 hours, returning to baseline values.43,44
In Phase III trials, symptomatic bradycardia after the 
first dose of fingolimod, mainly dizziness, chest discom-
fort, or palpitations, was observed in ,1% of patients. No 
cases of syncope have been observed. Most events were 
mild-to-moderate in severity and resolved within 24 hours 
without requiring pharmacological interventions. There 
were no episodes of symptomatic bradycardia occurring 
beyond 24 hours and no clinically significant effects on 
heart rate were observed with sustained administration of 
the drug.43,44 Although during these clinical trials, pharma-
cological treatment was not required to treat bradycardia, it 
has been suggested that intravenous atropine can ameliorate 
the negative effect of fingolimod on cardiac rhythm.45 In 
addition to transient changes in cardiac rhythm, fingolimod 
induced cardiac conduction abnormalities. In the Phase III 
trials, first- and second-degree atrioventricular blocks were 
infrequently reported (0.4%–1.4% of patients) and these 
were not symptomatic. However, in the FREEDOMS study, 
electrocardiography performed on day 1 post-dosing revealed 
first- and second-degree atrioventricular block in 7% and 
0.6% of patients, respectively. No effect on atrioventricular 
conduction was observed with continued treatment beyond 
24 hours.43,44 Initial administration of fingolimod was also 
associated with a mild reduction in mean arterial blood pres-
sure within 4–5 hours post-dosing. This transient reduction in 
mean arterial pressure was followed by a small and sustained 
increase (2–3 mmHg over the baseline values) during the 
first 6 months of treatment, with no further changes in the 
subsequent months. In the Phase III trials, hypertension was 
reported in 4%–6% of participants.43,44
Malignant neoplasms were reported in patients undergo-
ing therapy with fingolimod in the Phase III trials, including 
localized skin cancer (Bowen’s disease: 1 case; basal cell 
carcinoma: 10 cases; malignant melanoma: 4 cases), all of 
which were successfully excised, and breast cancer (5 cases). 
One woman died from metastatic breast cancer 10 months 
after discontinuing fingolimod .43 Both skin and breast cancer 
were also reported in the control groups (6 and 3 cases in 
total, respectively). The number of events was not enough to 
establish a statistical association between fingolimod and the 
risk of cancer in clinical trials. However, further  long-term 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
183
Fingolimod for treatment of multiple sclerosis
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
7.
10
8.
70
.6
 o
n 
09
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Drug Design, Development and Therapy 2012:6
observation is needed before definitive conclusions can be 
detected.
Besides more frequent serious AEs, there were two cases 
of particular interest during these clinical trials. One case of 
posterior reversible encephalopathy syndrome occurred in a 
woman with no evident predisposing factors after 10 weeks 
of treatment with 5 mg of fingolimod. The symptoms and 
MRI abnormalities improved 72 hours after discontinuation 
of medication, leaving residual neurological deficits.44
A case of temporo-occipital hemorrhagic and centrally 
necrotic focal encephalitis of unknown etiology was reported 
in a woman after 7 months of treatment with 1.25 mg 
of  fingolimod. Although bacterial and viral causes were 
excluded, antimicrobial treatment was administered. The 
patient recovered with sequelae.46
Conclusion
While the availability of oral therapies has been much 
anticipated by physicians and patients, in the clinical practice, 
neurologists will need to be cautious in selecting a therapy 
that may appear to have efficacy and convenience advantages 
versus current therapies, but may also carry unexpected safety 
and tolerability concerns. We do not yet know whether or 
not AEs seen in the recently published trials of fingolimod 
are the only safety issues to consider. The decision to use 
these new therapies will most likely be based on an overall 
assessment of efficacy, safety, tolerability, and adherence 
over the postmarketing period.
Keeping in mind the two different approval releases in 
the US (first-line treatment) and European countries (second-
line treatment),47 the following key questions still need to 
be answered before the treating neurologist is able to make 
evidence-based decisions:
•	 Considering the approval in the US: does fingolimod have 
a positive benefit–risk ratio compared with the established 
first-line DMDs?
•	 Which treatment shall we choose?
With regard to the first question, we have learned from 
the still unsolved and ongoing natalizumab studies that we 
are not able to anticipate the long-term safety.
Targeting lymphatic S1P1 receptor is preferential to 
targeting naïve and central memory T cells, except for the 
effector memory T cell population. This could potentially 
result in a selective mode of action targeting autoimmu-
nity and preserving key responses of the adaptive immunity 
relevant for viral defense. However, these concepts and treat-
ment rationales still need to be confirmed by data from the 
postmarketing period. Occurrence of herpes virus infections, 
as seen among patients receiving fingolimod, indicate a 
potential alteration of endogenous viral immunosurveillance. 
Further safety concerns include the risk of macular edema, 
the effect on lung function, and cancers. In addition, several 
cases of cardiological AEs have been reported, including 
symptomatic bradycardia after the first dose. Some deaths 
were also recently reported and further investigations are 
ongoing in order to define the exact relationship between 
these deaths and the use of fingolimod. This becomes more 
meaningful if we consider that the European Medicines 
Agency has recently advised clinicians to increase monitor-
ing of patients after the first dose.48
Moreover, data on teratogenicity is limited and although 
effective contraceptive measures are mandatory during 
and for 2 months after treatment discontinuation, cases of 
pregnancy in this cohort of patients will most likely occur, 
with uncertain consequences for the unborn child. Newer 
agents, which are more selective for the different types of 
S1P receptors, are currently in development to minimize the 
AEs observed with fingolimod.49
Therefore, will the benefits outweigh the risks during a 
long-term period of treatment in the individual patient? We 
believe that at the moment, the data available are not suf-
ficient to answer this question. Therefore, in our opinion, 
these issues will need to be discussed with the well-informed 
patient before considering fingolimod as a first-line choice 
in the treatment of MS.
On the other hand, European countries now have at their 
disposal two second-line treatment options (natalizumab 
and fingolimod), for highly active MS patients or patients 
not tolerating or not responding to first-line DMDs. Both 
drugs have been proven to be highly effective, although 
direct comparative head-to-head clinical trials have not yet 
been  undertaken. Thus, with regard to the second key ques-
tion – which compound to choose for this indication – the 
final decision will be based on benefit–risk considerations in 
the individual patient. The first prerequisite for an evidence-
based decision for the individual should be head-to-head 
clinical trials comparing the two compounds in efficacy. 
Postmarketing experience will be able to demonstrate the 
safety profile of fingolimod, while attempts to stratify patients 
at risk of PML treated with natalizumab are on the way. In 
future we foresee the possibility of switching therapy from 
natalizumab to fingolimod in those patients who present a 
high-risk profile in continuing therapy with natalizumab.
These approaches may in the future lead toward individual-
ized treatment, where data from the patient’s history and expo-
sure to specific infectious agents (such as JC virus serology) 
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could be taken into account to find the best treatment for the 
individual patient. Until these promising future tools are vali-
dated and have been proven to be applicable in daily clinical 
practice, the correct individual treatment decisions can only 
be made via dialog with the well-informed patient.
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The authors report no conflicts of interest in this work.
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